Literature DB >> 29138286

Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics.

Sarah Billington1, Adrian S Ray1, Laurent Salphati1, Guangqing Xiao1, Xiaoyan Chu1, W Griffith Humphreys1, Mingxiang Liao1, Caroline A Lee1, Anita Mathias1, Cornelis E C A Hop1, Christopher Rowbottom1, Raymond Evers1, Yurong Lai1, Edward J Kelly1, Bhagwat Prasad1, Jashvant D Unadkat2.   

Abstract

Protein expression of major hepatobiliary drug transporters (NTCP, OATPs, OCT1, BSEP, BCRP, MATE1, MRPs, and P-gp) in cancerous (C, n = 8) and adjacent noncancerous (NC, n = 33) liver tissues obtained from patients with chronic hepatitis C with hepatocellular carcinoma (HCV-HCC) were quantified by LC-MS/MS proteomics. Herein, we compare our results with our previous data from noninfected, noncirrhotic (control, n = 36) and HCV-cirrhotic (n = 30) livers. The amount of membrane protein yielded from NC and C HCV-HCC tissues decreased (31%, 67%) relative to control livers. In comparison with control livers, with the exception of NTCP, MRP2, and MATE1, transporter expression decreased in NC (38%-76%) and C (56%-96%) HCV-HCC tissues. In NC HCV-HCC tissues, NTCP expression increased (113%), MATE1 expression decreased (58%), and MRP2 expression was unchanged relative to control livers. In C HCV-HCC tissues, NTCP and MRP2 expression decreased (63%, 56%) and MATE1 expression was unchanged relative to control livers. Compared with HCV-cirrhotic livers, aside from NTCP, OCT1, BSEP, and MRP2, transporter expression decreased in NC (41%-71%) and C (54%-89%) HCV-HCC tissues. In NC HCV-HCC tissues, NTCP and MRP2 expression increased (362%, 142%), whereas OCT1 and BSEP expression was unchanged. In C HCV-HCC tissues, OCT1 and BSEP expression decreased (90%, 80%) relative to HCV-cirrhotic livers, whereas NTCP and MRP2 expression was unchanged. Expression of OATP2B1, BSEP, MRP2, and MRP3 decreased (56%-72%) in C HCV-HCC tissues in comparison with matched NC tissues (n = 8), but the expression of other transporters was unchanged. These data will be helpful in the future to predict transporter-mediated hepatocellular drug concentrations in patients with HCV-HCC.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29138286      PMCID: PMC5776333          DOI: 10.1124/dmd.117.077289

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  62 in total

1.  Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development.

Authors:  Kazuhiko Hanada; Kenya Nakai; Hiromasa Tanaka; Fumitaka Suzuki; Hiromitsu Kumada; Yasuo Ohno; Shogo Ozawa; Hiroyasu Ogata
Journal:  Drug Metab Pharmacokinet       Date:  2011-12-13       Impact factor: 3.614

2.  An analysis of 412 cases of hepatocellular carcinoma at a Western center.

Authors:  Y Fong; R L Sun; W Jarnagin; L H Blumgart
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

3.  Estimating progression to cirrhosis in chronic hepatitis C virus infection.

Authors:  A J Freeman; G J Dore; M G Law; M Thorpe; J Von Overbeck; A R Lloyd; G Marinos; J M Kaldor
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

4.  Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.

Authors:  Azusa Kitao; Yoh Zen; Osamu Matsui; Toshifumi Gabata; Satoshi Kobayashi; Wataru Koda; Kazuto Kozaka; Norihide Yoneda; Tatsuya Yamashita; Shuichi Kaneko; Yasuni Nakanuma
Journal:  Radiology       Date:  2010-07-27       Impact factor: 11.105

5.  Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.

Authors:  Brandon Swift; Noelia Nebot; Jin Kyung Lee; Tianxiang Han; William R Proctor; Dhiren R Thakker; Dieter Lang; Martin Radtke; Mark J Gnoth; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2013-03-12       Impact factor: 3.922

6.  The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma.

Authors:  Stephan R Vavricka; Diana Jung; Michael Fried; Uwe Grützner; Peter J Meier; Gerd A Kullak-Ublick
Journal:  J Hepatol       Date:  2004-02       Impact factor: 25.083

Review 7.  The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?

Authors:  Boone Goodgame; Nicholas J Shaheen; Joseph Galanko; Hashem B El-Serag
Journal:  Am J Gastroenterol       Date:  2003-11       Impact factor: 10.864

8.  Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics.

Authors:  Li Wang; Carol Collins; Edward J Kelly; Xiaoyan Chu; Adrian S Ray; Laurent Salphati; Guangqing Xiao; Caroline Lee; Yurong Lai; Mingxiang Liao; Anita Mathias; Raymond Evers; William Humphreys; Cornelis E C A Hop; Sean C Kumer; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2016-08-19       Impact factor: 3.922

9.  Sofosbuvir/velpatasvir: A promising combination.

Authors:  Aldo Bonaventura; Fabrizio Montecucco
Journal:  World J Hepatol       Date:  2016-07-08

10.  Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1.

Authors:  Anne T Nies; Mikko Niemi; Oliver Burk; Stefan Winter; Ulrich M Zanger; Bruno Stieger; Matthias Schwab; Elke Schaeffeler
Journal:  Genome Med       Date:  2013-01-11       Impact factor: 11.117

View more
  16 in total

1.  Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1.

Authors:  Mingqing Chen; Claudia Neul; Elke Schaeffeler; Franziska Frisch; Stefan Winter; Matthias Schwab; Hermann Koepsell; Shuiying Hu; Stefan Laufer; Sharyn D Baker; Alex Sparreboom; Anne T Nies
Journal:  Clin Pharmacol Ther       Date:  2019-09-03       Impact factor: 6.875

2.  Characterization of Plasma Membrane Localization and Phosphorylation Status of Organic Anion Transporting Polypeptide (OATP) 1B1 c.521 T>C Nonsynonymous Single-Nucleotide Polymorphism.

Authors:  Alexandra Crowe; Wei Zheng; Jonathan Miller; Sonia Pahwa; Khondoker Alam; Kar-Ming Fung; Erin Rubin; Feng Yin; Kai Ding; Wei Yue
Journal:  Pharm Res       Date:  2019-05-15       Impact factor: 4.200

3.  Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs.

Authors:  Mengbi Yang; Xin Xu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2022-09-09       Impact factor: 4.936

4.  Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Authors:  Raymond Evers; Micheline Piquette-Miller; Joseph W Polli; Frans G M Russel; Jason A Sprowl; Kimio Tohyama; Joseph A Ware; Saskia N de Wildt; Wen Xie; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

5.  Targeted LC-MS/MS Proteomics-Based Strategy To Characterize in Vitro Models Used in Drug Metabolism and Transport Studies.

Authors:  Meijuan Xu; Neha Saxena; Marc Vrana; Haeyoung Zhang; Vineet Kumar; Sarah Billington; Cyrus Khojasteh; Scott Heyward; Jashvant D Unadkat; Bhagwat Prasad
Journal:  Anal Chem       Date:  2018-09-28       Impact factor: 6.986

6.  STAT3 signaling pathway plays importantly genetic and functional roles in HCV infection.

Authors:  Yuzhu Song; Xianyao Yang; Yunsong Shen; Yiqian Wang; Xueshan Xia; A-Mei Zhang
Journal:  Mol Genet Genomic Med       Date:  2019-06-20       Impact factor: 2.183

Review 7.  Extrahepatic Drug Transporters in Liver Failure: Focus on Kidney and Gastrointestinal Tract.

Authors:  Marek Droździk; Stefan Oswald; Agnieszka Droździk
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

Review 8.  Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.

Authors:  Stephan Urban; Christoph Neumann-Haefelin; Pietro Lampertico
Journal:  Gut       Date:  2021-06-08       Impact factor: 23.059

9.  Mass spectrometry-based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin.

Authors:  Zubida M Al-Majdoub; Brahim Achour; Narciso Couto; Martyn Howard; Yasmine Elmorsi; Daniel Scotcher; Sarah Alrubia; Eman El-Khateeb; Areti-Maria Vasilogianni; Noura Alohali; Sibylle Neuhoff; Lutz Schmitt; Amin Rostami-Hodjegan; Jill Barber
Journal:  FEBS Lett       Date:  2020-12-03       Impact factor: 3.864

10.  Hepatic drug-metabolizing enzymes and drug transporters in Wilson's disease patients with liver failure.

Authors:  Sylwia Szeląg-Pieniek; Stefan Oswald; Mariola Post; Joanna Łapczuk-Romańska; Marek Droździk; Mateusz Kurzawski
Journal:  Pharmacol Rep       Date:  2021-06-11       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.